Get the Stockscreener App
34.86
1.81%
0.62
After Hours:
34.86
Newamsterdam Pharma Company Nv stock is traded at $34.86, with a volume of 443.67K.
It is up +1.81% in the last 24 hours and up +6.64% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$34.24
Open:
$34.26
24h Volume:
443.67K
Relative Volume:
0.52
Market Cap:
$3.95B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-16.21
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
+8.73%
1M Performance:
+6.64%
6M Performance:
+39.44%
1Y Performance:
+79.97%
1-Day Range:
$34.10
$35.62
1-Week Range:
$32.15
$35.62
52-Week Range:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
34.86 | 3.88B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Aug-25-25 | Initiated | Wells Fargo | Overweight |
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
Momentum Shift: Should I trade or invest in NewAmsterdam Pharma Company NV2025 Support & Resistance & Reliable Momentum Entry Alerts - baoquankhu1.vn
Breakouts Watch: Will NewAmsterdam Pharma Company NV benefit from sector rotationBond Market & Fast Gain Stock Tips - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Keybank National Association OH Acquires New Stake in NewAmsterdam Pharma Company N.V. $NAMS - Defense World
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit - The Manila Times
Understanding Momentum Shifts in (NAMS) - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Stock Analysis: Healthcare Innovator with 54% Potential Upside - DirectorsTalk Interviews
Published on: 2026-02-02 19:49:09 - baoquankhu1.vn
Aug Highlights: Should I trade or invest in NewAmsterdam Pharma Company NV2025 Breakouts & Breakdowns & Stepwise Swing Trade Plans - baoquankhu1.vn
Atle Fund Management AB Purchases 36,402 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Louise Frederika Kooij Sells 39,816 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - Defense World
Buyback Watch: What are the risks of holding NewAmsterdam Pharma Company NV Equity WarrantJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Take Profit: Can NewAmsterdam Pharma Company NV benefit from deglobalizationJuly 2025 Selloffs & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 39,816 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,037,061.60 in Stock - MarketBeat
Will NewAmsterdam Pharma Company N.V. stock recover after earningsWeekly Trade Report & Capital Protection Trading Alerts - mfd.ru
(NAMSW) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is NewAmsterdam Pharma Company N.V.’s ROIC above industry averageEarnings Growth Summary & Step-by-Step Swing Trade Plans - mfd.ru
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 38,172 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Gem With 52% Upside Potential - DirectorsTalk Interviews
Bond Watch: Is ACOG a good ESG investment2025 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
Quarterly Recap: Is ESLT benefiting from innovation trendsTake Profit & Weekly Top Stock Performers List - baoquankhu1.vn
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Jennison Associates LLC - MarketBeat
Avoiding Lag: Real-Time Signals in (NAMS) Movement - Stock Traders Daily
Stock Recap: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trendsMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
Update Report: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trends2025 Market WrapUp & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Assessing NewAmsterdam Pharma Co: Insights From 5 Financial Analysts - Benzinga
NewAmsterdam Pharma (NAMS) Stock Analysis: Evaluating The 52.72% Potential Upside - DirectorsTalk Interviews
Risks Report: Does HONDW stock have upside surprise potentialEarnings Overview Summary & Accurate Buy Signal Alerts - baoquankhu1.vn
Responsive Playbooks and the NAMSW Inflection - Stock Traders Daily
Aug Intraday: Will NewAmsterdam Pharma Company NV benefit from seasonalityJuly 2025 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Fed Meeting: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskPortfolio Return Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn
Gains Report: What is the implied volatility of Drugs Made In America Acquisition Corp Equity RightWeekly Trade Analysis & AI Enhanced Execution Alerts - baoquankhu1.vn
Exit Recap: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskBear Alert & AI Enhanced Trading Alerts - baoquankhu1.vn
First Week of March 20th Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq
Relative Strength Alert For NewAmsterdam Pharma Company - Nasdaq
Aug Action: Does NewAmsterdam Pharma Company NV Equity Warrant align with a passive investing strategy2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility - Yahoo Finance
Aug Rallies: How NewAmsterdam Pharma Company NV stock compares to market leadersPortfolio Update Summary & High Return Trade Guides - Bộ Nội Vụ
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech With 46% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in NAMS Response - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.5%Time to Sell? - MarketBeat
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com Australia
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress - TipRanks
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative
Drug in late-stage tests cuts cholesterol and an Alzheimer’s marker - Stock Titan
Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - Улправда
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru
Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - Улправда
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):